We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genincode Plc | LSE:GENI | London | Ordinary Share | GB00BL97B504 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.25 | 4.67% | 5.60 | 270,300 | 10:43:50 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 5.20 | 6.00 | 5.60 | 5.35 | 5.35 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 1.43M | -5.56M | -0.0580 | -0.97 | 5.37M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:43:49 | O | 8,750 | 5.60 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 29/11/2023 | 18:07 | ALNC |  TRADING UPDATES: Aura eyes Tiris expansion; Kavango backs Pambili |
| 29/11/2023 | 07:10 | UKREG | GENinCode PLC CARDIO inCode-Score 510(k) FDA submission update |
| 29/11/2023 | 07:00 | UKREG | GENinCode PLC Change of Adviser |
| 12/10/2023 | 06:00 | RNSNON | GENinCode PLC ShareSoc investor presentation |
| 20/9/2023 | 15:24 | ALNC | EARNINGS: ASA interim profit plummets; Mycelx loss narrows, revenue up |
| 20/9/2023 | 06:00 | UKREG | GENinCode PLC Half-year Report |
| 13/9/2023 | 06:00 | UKREG | GENinCode PLC Notice of Results |
| 30/8/2023 | 06:00 | UKREG | GENinCode PLC Presentation at European Society of Cardiology |
| 16/8/2023 | 11:41 | DJN | GENinCode Shares Rise on FDA Filing for Heart Disease Test Kit |
| 16/8/2023 | 09:27 | UKREG | GENinCode PLC CARDIO inCode 510k filing |
Genincode (GENI) Share Charts1 Year Genincode Chart |
|
1 Month Genincode Chart |
Intraday Genincode Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 12:43:50 | 5.60 | 8,750 | 490.00 | O |
| 11:43:43 | 5.78 | 127,068 | 7,338.18 | O |
| 11:39:52 | 5.60 | 10,000 | 560.00 | O |
| 11:04:50 | 5.85 | 33,982 | 1,987.95 | O |
| 10:37:07 | 5.70 | 100 | 5.70 | O |
| Top Posts |
|---|
Posted at 08/12/2023 08:20 by Genincode Daily Update Genincode Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GENI. The last closing price for Genincode was 5.35p.Genincode currently has 95,816,866 shares in issue. The market capitalisation of Genincode is £5,365,744. Genincode has a price to earnings ratio (PE ratio) of -0.97. This morning GENI shares opened at 5.35p |
Posted at 07/12/2023 18:26 by jimtech I'm positive and have recently bought in but it's going to take some time.Have only taken a half position as fundraise larger than their current MCap (£5m) is required. They will likely hope FDA kit approval and resulting RNS will boost share price so they can raise. This, of course, assumes approval. Patience required. And maybe more funds. |
Posted at 14/10/2023 13:45 by timbo003 Register for the seminar mentioned in the previous post (which includes a presentation from GENI) here: |
Posted at 14/10/2023 10:45 by sharesoc ShareSoc is holding its first hybrid event in London on 19th Oct. Hear from GENincode (GENI) and other healthcare companies like Tristel Plc (TSTL), Inspiration Healthcare Group (IHC), Creo Medical Group (CREO) and Abingdon Health (ABDX). Attend in-person or online.📍 |
Posted at 30/8/2023 06:18 by toffeeman Nice RNS this morning - but will it impact the share price? |
Posted at 06/4/2022 16:50 by hedgehog 100 06/04/2022 07:01 UK Regulatory (RNS & others) GENinCode PLC Director Appointment LSE:GENI Genincode PlcOxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the appointment to the Board of Felix Frueh , PhD ("Felix") as a Non-Executive Director. Felix is a senior life sciences executive with in-depth expertise in corporate, regulatory, and commercialisation strategies, with a particular focus on precision medicine. He has over 25 years of experience setting scientific and corporate strategy in precision medicine, and has founded several start-ups in the diagnostics and pharmaceutical sectors. He has worked in the regulatory space for 18 years, including five years working with the FDA. In addition to his FDA career, Felix oversaw the creation and operations of the world's largest next-generation, Clinical Laboratory Improvement Amendments (CLIA)-certified, whole human genome sequencing laboratory, as the Chief Scientific Officer of Human Longevity (HLI). Prior to this, he served as President of Medco Research Institute, Research Director for Pharmacogenetics of Transgenomic, and Assistant Director of Protogene Laboratories. He is Founder and Executive Partner of Opus Three, Co-Founder and Partner of Profound Ventures, and Co-Founder and Chief Scientific Officer of Selva Therapeutics. He also co-founded and formerly served as the Chief Executive Officer of Intellos Health. Felix received his PhD in biochemistry from the University of Basel in Switzerland and completed postdoctoral fellowships at the University of Basel and Stanford University. He has served as a consultant, strategic advisor, and Board member to numerous diagnostic, pharmaceutical, and other healthcare companies. He is the author of more than 100 peer-reviewed articles, book chapters, white papers, market analyses, strategies, and business plans. Matthew Walls, CEO of GENinCode Plc commented : " We are delighted that Felix is joining as a Non-Executive Director. Felix can offer us invaluable insights into the FDA as we start to look towards commericalisation in the US later this year, and his many years of experience in key roles in the industry will be a huge benefit to us. His depth of knowledge in precision medicine and regulatory affairs is second-to-none and we are looking forward to capitalising on his expertise." Bill Rhodes, Non-Executive Chairman of GENinCode Plc, commented: "Our goal is to improve the current standard of care in cardiovascular disease worldwide through our unique portfolio of products, and Felix has the experience and expertise to help us achieve this. I am looking forward to working with him, as is the entire GENincode team, and welcome him to the Board." Felix Frueh , PhD added: "I am thrilled to have been asked to join the Board of GENinCode at this critical stage. I have spent most of my career in the precision medicine space and feel I can add real value to the team." Regulatory disclosures The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Felix Wilhelm Frueh, aged 54: Current Directorships Previous Directorships Opus Three Partners LLC Intellos Health LLC Selva Therapeutics Enterome SA Bloom Science, Inc. Ariana Pharmaceuticals SA AZCERT As of the date of this announcement, Felix Frueh holds no ordinary shares in the capital of the Company. Save as disclosed above there are no additional disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies. For more information visit www.genincode.com |
Posted at 23/3/2022 08:26 by hedgehog 100 23/03/2022 07:00 UK Regulatory (RNS & others) GENinCode PLC Indiana University Medical School collaboration LSE:GENI Genincode PlcCollaboration with Indiana University School of Medicine Study for testing Cardio inCode-SCORE for the risk of onset of cardiovascular disease Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces its collaboration with the Indiana University School of Medicine ("IU"). IU is the largest medical school in the US and will undertake a 'Proof of Concept' study using Cardio inCode-SCORE for the risk assessment of patients for onset of atherosclerotic cardiovascular disease ("ASCVD "). ASCVD accounts for over 85% of all cardiovascular disease deaths and is the leading cause of morbidity and mortality in the US and globally. According to the Centres for Disease Control and Prevention ("CDC"), cardiovascular disease ("CVD") is the number one cause of death in the United States and the decades--long trend towards lower cardiovascular mortality rates has begun to reverse, with an increase in total mortality during recent years: hxxps://www.cdc.gov/ CVD disproportionately affects people of lower socioeconomic status, and those of non--white ethnicity. Early identification of subclinical disease in the population can lead to better primary prevention of heart attack and stroke. Current American College of Cardiology ("ACC") guidelines call for risk stratification using validated instruments, such as the US National Heart Lung and Blood Institute ("NHLBI") pooled risk cohort equation, drawing on clinical parameters readily available such as blood pressure and cholesterol levels. In addition, the guidelines endorse the use of "risk enhancing factors" such as the Coronary Artery Calcium ("CAC") score, undertaken using computerised tomography ("CT") imaging of the coronary arteries. Whilst acknowledging family history as a risk factor, current guidelines have not yet incorporated the potential of genetic risk assessment in the prediction of ASCVD. Cardio inCode-SCORE provides an opportunity to apply advanced polygenic testing to improve patient risk assessment and prognosis, in a widely available form and at reduced cost compared with other test modalities. The primary aim of the IU study is to evaluate the association between the Cardio inCode-SCORE genetic risk score ("GRS") and the presence of subclinical coronary atherosclerosis evaluated by CAC. CVD is a broad disease classification which encompasses conditions such as coronary artery disease (causing angina, heart attacks, heart failure), cerebrovascular disease (causing stroke, and some dementia), peripheral vascular disease (causing limb ischemia, and some chronic kidney disease) and venous thromboembolism. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. According to the US National Institutes of Health ("NIH"), by 2030, the global cost of CVD is set to rise to US$1,044 billion, from approximately US$863 billion in 2010, and is both a major health issue and global economic burden. GENinCode has a vision to assist clinicians and inform patients about cardiovascular risk, and to improve public health using the predictive capability of genomics. High genetic risk patients are assisted in making lifestyle choices and can receive targeted treatment to improve outcomes. Over the past 15 years , GENinCode has made a substantial investment in its research, bioinformatic data, technology, and product development to assess disease risk, in order to help clinicians and patients prevent the onset of CVD. Matthew Walls, CEO, GENinCode said: "We are delighted to work with the IU School of Medicine and to introduce Cardio inCode-SCORE to the IU health community. The IU study follows on from our recently published US clinical performance studies showing the substantive predictive capability of the Cardio inCode-SCORE product for the risk assessment of patients for the onset of cardiovascular disease. We look forward to working closely with the IU team to successfully deliver the programme ." Richard Kovacs MD, Q.E. and Sally Russell Professor of Cardiology in the Division of Cardiovascular Disease at IU School of Medicine commented: "The GENinCode and IU collaboration offers the potential to improve the prediction of ASCVD and better assess patient risk of future CVD events. GRS's provide an opportunity to enhance assessment of risk based on 'classic' CVD risk factors and help physicians identify patients at higher inherited genetic risk, thereby targeting improved treatment and reduction in future CVD events. IU welcomes this approach and we look forward to working with Cardio inCode-SCORE to advance preventative CVD care." For more information visit www.genincode.com |
Posted at 15/3/2022 10:04 by hedgehog 100 15/03/2022 07:00 UK Regulatory (RNS & others) GENinCode PLC Lipid inCode pilot LSE:GENI Genincode PlcNHS pilot for polygenic testing of UK patients suffering with hypercholesterolemia and familial hypercholesterolemia Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces a collaboration with the Academic Health Science Network for the North East and North Cumbria ("AHSN NENC") to pilot the use of its Lipid inCode(R) test for the diagnosis of hypercholesterolemia (high levels of cholesterol) and familial hypercholesterolemia ("FH"). There are 15 Academic Health Science Networks ("AHSN") across England, established by NHS England in 2013 to spread innovation at pace and scale - improving health and generating economic growth. Each AHSN works across a distinct geography serving a different population in each region. The AHSN NENC leads a national AHSN programme aimed at identification of FH and lipid management, in collaboration with the Accelerated Access Collaborative (AAC) and the National Institute for Health & Care Excellence (NICE). The launch of Lipid inCode(R) marks the introduction of GENinCode's first UK polygenic product aimed at improving the diagnosis and treatment of hypercholesterolemia and preventing the onset of cardiovascular disease ("CVD"). Following the successful completion and positive results of its NHS clinical study (1) of the Lipid inCode(R) test, the AHSN NENC collaboration will undertake a short term pilot using Lipid inCode(R) in primary care and community practice to help in the detection and diagnosis of people with high cholesterol, a known important risk factor for the development of CVD. Improved detection will also support better treatment and preventative care. Lipid inCode(R) offers genetic testing for the causes of high cholesterol, with rapid results and a comprehensive report provided to clinicians. Lipid inCode(R) will be offered at a reduced cost to the NHS to help support its declared ambition to detect 25% of people with FH by 2024. In the UK around 7.6m people live with heart and circulatory disease, which causes 25% of all deaths annually in the UK. CVD can be reduced by identifying and treating individuals at risk, and the NHS 10 Year Plan (2019) sets out significant ambitions to address the CVD prevention, including identifying individuals with hypercholesterolemia and particularly those with FH. FH is an inherited monogenic condition which affects an individual's ability to regulate and remove cholesterol from their blood. FH affects approximately 1 in 250 people in the UK population and globally. The NHS Long Term Plan sets out to expand access to genetic testing for FH, which causes early heart attacks and sudden cardiac death. Individuals suffering with FH have a higher risk of heart disease and death at a younger age. For individuals suffering with FH it is important to lower their cholesterol to healthy levels as early in life as possible, often requiring medicines such as statins or more aggressive treatment to help better control cholesterol levels. CVD is a broad disease classification which encompasses conditions such as coronary artery disease (causing angina, heart attacks, heart failure), cerebrovascular disease (causing stroke, and some dementia), peripheral vascular disease (causing limb ischemia, and some chronic kidney disease) and venous thromboembolism. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. According to the US National Institutes of Health (NIH), by 2030, the global cost of CVD is set to rise to US$1,044 billion, from approximately US$863 billion in 2010, and is both a major health issue and global economic burden. GENinCode has a vision to assist clinicians and inform patients in interpreting cardiovascular risk, and to improve public health using the predictive capability of genomics. High genetic risk patients are assisted in making lifestyle choices and can receive targeted treatment to improve outcomes. Over the past 15 years GENinCode has made a substantial investment in its research, bioinformatic data, technology, and product development to assess disease risk, in order to help clinicians and patients prevent the onset of CVD. Matthew Walls, CEO, GENinCode said: "The AHSN NENC pilot marks the beginning of our Lipid inCode(R) diagnostic testing for hypercholesterolemia and familial hypercholesterolemia sufferers and we look forward to supporting the NHS in reaching its goals to diagnose patients with hypercholesterolemia Professor Julia Newton, Medical Director at AHSN NENC commented: "We are delighted to pilot Lipid inCode(R) to advance the diagnosis and treatment of hypercholesterolemia and familial hypercholesterolemia For more information visit www.genincode.com |
Posted at 15/12/2021 14:57 by hedgehog 100 At just 33.5p the GENI share price is getting a bit silly now.The IPO on 22nd. July was at 44p, and that looked a bargain. Since when there has been steady progress. I'm a big fan of 'overhang plays', because when the supply of cheap shares dries up, the share price can rebound quite dramatically, which is what I fully expect to happen here. |
Posted at 06/12/2021 09:28 by hedgehog 100 29/11/2021 07:00 UK Regulatory (RNS & others) GENinCode PLC Directorate Change LSE:GENI Genincode Plc"GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces that David Evans, Non-Executive Director, has notified the Board of his intention to stand down from his role with immediate effect. Bill Rhodes, Non-Executive Chairman of GENinCode Plc said: " We would like to thank David for his invaluable contribution to GENinCode during his tenure. David has worked with members of the GENinCode management team for many years, and he has always provided instrumental strategic advice and counsel from his wealth of experience in the sector. On behalf of the Board, I would like to wish him the very best for the future."" No I don't think he'll be selling any time soon. Like most people here I imagine, I think he'll be intending to wait until GENI progresses its business plan, and hopefully multibags, before selling any. It could be that he always intended stepping down at some point relatively soon after GENI floated, having helped the company achieve this important milestone, and being very busy. GENI still has five directors, and the board looks very strong. But the opportunity acquire more cheap GENI shares, with fewer restrictions, could have been an additional inducement. Either for his own account, and/or for his Intuitive Investments (IIG) life sciences fund. And investment in GENI from IIG would make perfect sense, and stepping down as a GENI director could simplify this. |
Posted at 31/10/2021 12:09 by hedgehog 100 22/07/2021 07:00 UK Regulatory (RNS & others) GENinCode PLC Admission to trading on AIM & First Day of Dealing LSE:GENI Genincode Plc"... On 28 April 2021, the Company announced a partnership to provide genetic testing from labs based at Royal Brompton and Harefield Hospitals. Following this, it was announced on 14 June 2021 that a product commercialisation agreement had been entered into with EVERSANA in the US. The Directors believe that the partnership with EVERSANA, a leading provider of global commercial services to the life science industry, will provide a significant opportunity for the Group to progress its commercialisation plans for the US. ..." "GENinCode announces major US commercialisation partnership with EVERSANA Posted on June 14, 2021 Oxford, UK. — 14, June 2021 — GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces its partnership with EVERSANA Life Sciences LLC (“EVERSANA&rdq EVERSANA is a leading provider of global commercial services to the life sciences industry. In the United States, GENinCode will utilise EVERSANA’s COMPLETE Commercialisation model fully integrating services that include market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, health economics and outcomes research and compliance, with each service optimised by data and predictive analytics. The suite of expertise will underpin and accelerate the launch of GENinCode’s first product Cardio inCode for the risk assessment of CVD in primary prevention. The EVERSANA group comprises over 4,000 employees. GENinCode specialises in polygenic risk assessment for the onset of cardiovascular disease with the Company’s technology providing clinicians with genetic risk assessment and AI bioinformatics to inform, predict and prevent cardiovascular events. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. In 2010, the global cost of CVD was approximately US $863 billion. By 2030, this figure is set to rise to US $1,044 billion and is both a major health issue and global economic burden. CVD is a broad disease classification which encompasses conditions such as coronary artery disease (causing angina, heart attacks, heart failure), cerebrovascular disease (causing stroke, and some dementia), peripheral vascular disease (causing limb ischaemia, and some chronic kidney disease) and venous thromboembolism. GENinCode will deliver its portfolio of polygenic CVD products through its partnership with EVERSANA. GENinCode and EVERSANA have a vision to inform patients about their cardiovascular risk and to improve public health by using the predictive capability of genomics to assist in making lifestyle choices and targeting treatment to improve patient outcomes. Over the past 15 years GENinCode has amassed significant investment in its research, data, bioinformatics technology and product development to assess disease risk to prevent the onset of CVD. Matthew Walls, CEO, GENinCode said: “We have worked closely with the EVERSANA team over the past 12 months and are delighted to announce our US partnership. EVERSANA provide proven launch and commercialisation expertise to support our market access and will help accelerate our speed to market.” Jim Lang, CEO of EVERSANA said: “GEN inCode’s approach to understanding and addressing genetic risk is revolutionary and as such, these products demand a commercialisation model that bypasses traditionally strategies to acceleration launch, access and impact. EVERSANA is eager to put the full power of our platform to work.” For more information visit www.genincode.com Enquiries: GENinCode UK Limited Tamsin Jeffs Tel +44 (0)7800 903435 EVERSANA Sarah Zwicky Tel +1 (414) 434-4691 About GENinCode GENinCode is a UK based company specializing in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode UK Limited operates business units in Europe and Latin America through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. GENinCode’s predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. To learn more about GENinCode, visit www.genincode.com or connect through LinkedIn and Twitter. About EVERSANA EVERSANA™ is the leading provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
